The Pharmalot View

By  Ed Silverman
VA veterans affairs building
Pharmalot

Medicare Part D could have saved $14.4 billion in 2016 by negotiating as the VA did

By Ed Silverman

New Opioid Approved - Dsuvia
The Pharmalot View

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

By Ed Silverman

Trump drug prices
The Pharmalot View

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

By Ed Silverman

GSK
The Pharmalot View

One of the world’s largest drug makers is paying docs again — and patients are the worse off

By Ed Silverman

Alex Gorsky
The Pharmalot View

From zero to hero: J&J CEO praises Trump one year after chastising him

By Ed Silverman

A photo of Pascal Soriot.
The Pharmalot View

When modest is actually excessive: AstraZeneca spins its price hikes

By Ed Silverman

President Trump Delivers Remarks On Lowering Drug Prices In Rose Garden
The Pharmalot View

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

By Ed Silverman

The Pharmalot View

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

By Ed Silverman

Dengvaxia
The Pharmalot View

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

By Ed Silverman

Soldiers silhouette
The Pharmalot View

The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

By Ed Silverman

Jerry Brown
The Pharmalot View

California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

By Ed Silverman

Dollars
The Pharmalot View

Here’s how a loophole in a transparency law can distort medical practices

By Ed Silverman

The Pharmalot View

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

By Ed Silverman

Novartis campus
The Pharmalot View

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

By Ed Silverman

The Pharmalot View

Drug makers deserve to be publicly shamed for thwarting competition from generics

By Ed Silverman

Handshake
The Pharmalot View

The art of the deal? Why a money-back guarantee for drugs is a bad idea

By Ed Silverman

Donald Trump
The Pharmalot View

If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

By Ed Silverman

Supplements
The Pharmalot View

It’s time to make it legal for Americans to order prescription drugs from abroad

By Ed Silverman

Aedes aegypti mosquitoes
The Pharmalot View

US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

By Ed Silverman

Hepatitis C protest
The Pharmalot View

The Trump administration could bring down drug prices. But it would take guts

By Ed Silverman

Scott Gottlieb
The Pharmalot View

Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

By Ed Silverman

Regeneron
The Pharmalot View

How a $37,000-a-year medicine sets a good model for drug pricing

By Ed Silverman

Paxil
The Pharmalot View

Here’s one drug safety rule the FDA should enact — quickly

By Ed Silverman

Trump
The Pharmalot View

Dear Mr. President: Your view of the FDA is misguided. Here’s why

By Ed Silverman

Mike Pence
The Pharmalot View

Dear Vice President Pence: Stop peddling false hopes to dying patients

By Ed Silverman

Stephen J. Ubl
The Pharmalot View

Pharma trade group vows to review membership criteria, but is this an empty promise?

By Ed Silverman

Trump pharma
The Pharmalot View

Dear President Trump: Your big idea on drug pricing is half-baked

By Ed Silverman

PHrMA GoBold
The Pharmalot View

Drug industry ad campaign may be too late to save its reputation

By Ed Silverman

Donald Trump
The Pharmalot View

Trump is considering a radical to lead FDA. That’s dangerous for public health

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy